Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2025The Annual Review of Pharmacology and Toxicology

Incretin Signaling Neighborhoods and Adverse Drug Reactions

View Full Paper
Ask AI
Bookmark
Share

Authors

SWShane C. WrightPLPeter LindquistMRMette M. Rosenkilde

Discussion

Loading...

Member takes

Overview

This review highlights the development of GLP-1 drugs and their effects on adverse drug reactions, suggesting differences in signaling pathways.

Key Points

  • Advancements in incretin therapies may improve treatment outcomes, yet they can induce adverse reactions.
  • Drug-induced changes in receptor landscapes can lead to varying side effects in patients using GLP-1 drugs.
  • Understanding pharmacogenomics is crucial for optimizing incretin mimetics and reducing negative drug reactions.
  • Differences in pathway selectivity significantly impact the efficacy and safety of incretin-based treatments.

Cite This Study

Wright et al. (2025) studied this question.

synapsesocial.com/papers/68d43b09713b0b5dfea7b179https://doi.org/10.1146/annurev-pharmtox-062124-015046
View Full Paper
Ask AI
Bookmark
Share